KHKent Heberer

Kent Heberer

*This is an algorithmically generated author record based on publicly available information.

Kent Heberer has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Menopausal status, hormonal therapy, and elevated lipoprotein(a): Implications for prevalent coronary artery disease in U.S. Women Veterans

    by Nallamshetty Shriram, Cogill Steven, Heberer Kent, Maldonado Ana I., Seshadri Anika, Chen Ying Q., Bress Adam, Lynch Julie A., Shih Mei-Chiung, Lee Jennifer S., et al.

    Aims: To determine whether menopausal status, menopausal hormone therapy (MHT), or oral contraceptive (OCP) use modifies the association between elevated Lp(a) and prevalent coronary artery disease (CAD). Methods: We conducted a cross-sectional study of 6,314 U.S. Women Veterans with Lp(a) testing from 1999-2025 to evaluate whether menopausal status, MHT use, or OCP use modify the association between elevated Lp(a) (≥ 125 nmol/L) and prevalent CAD. Logistic regression was used to estimate adjusted odds ratios (aOR), with interaction terms evaluated by likelihood ratio tests. Restricted cubic splines were used to model the continuous association between Lp(a) and prevalent CAD. Results: Elevated Lp(a) was present in 31.6% of Women Veterans and was independently associated with increased odds of prevalent CAD (aOR 1.24, 95% confidence interval 1.06-1.44, p = 0.0079). We observed a continuous increase in prevalent CAD with rising Lp(a) levels (aOR 1.023 per 25 nmol/L increase, 95% confidence interval 1.010-1.040, p = 0.0033). No effect modification was detected for menopausal status (p-value for interaction = 1.0), MHT use in postmenopausal women (p-value for interaction = 0.20), or OCP use in premenopausal women (p-value for interaction = 0.32). Conclusion: Elevated Lp(a) is common and associated with prevalent CAD in Women Veterans. We did not detect modification of the association between elevated Lp(a) and prevalent CAD based on menopausal status or hormonal therapy. These findings support systematic Lp(a) screening across the full female reproductive spectrum.

  • Open Access

    Semaglutide Initiation and Treatment Duration On Suicidality Risk in US Veterans With Type 2 Diabetes

    by Ana I. Maldonado, Kent R. Heberer, Julie A. Lynch, Steven Bradley Cogill, Shriram Nallamshetty, Ying Q. Chen, Mei-Chiung Shih, Adam P. Bress, Jennifer S. Lee

    Importance: Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), is a highly effective medication to treat type 2 diabetes and obesity. However, concerns about potential suicidality persist, creating clinical uncertainty about its neuropsychiatric safety. Objective: To assess risks of suicidality after initiating semaglutide compared to initiating SGLT2i and by duration of continuous semaglutide treatment. Design: Active-comparator, new-user target trial emulation to estimate inverse probability-weighted marginal cause-specific hazard ratios (HRs). For duration-of-treatment analyses, we used clone-censor-weight methods to estimate exposure-adjusted effects. Setting: Veterans Health Administration. Participants: U.S. Veterans with type 2 diabetes receiving care from March 1, 2018 to September 1, 2025. Exposure: Initiation of semaglutide vs SGLT2i; duration of semaglutide use (<=6, 7-12, >12 months). Outcomes: Incident suicidal ideation; suicide attempt or death; and a composite outcome. Results: A total of 102,361 Veterans met inclusion criteria, including 11,478 new initiators of semaglutide and 90,883 new initiators of an SGLT2i. After overlap weighting, baseline characteristics were well balanced between treatment groups (mean [SD] age, 60.1 [11.7] years; BMI, 37.8 [6.8] kg/m2; hemoglobin A1c, 7.0% [1.4]; 85.5% male; 61.9% non-Hispanic White). During a median follow-up of 2.2 years, 9077 incident suicidal ideation events and 696 suicide attempts or deaths occurred. The incidence rate of suicidal ideation was 56.3 and 37.7 per 1000 person-years among semaglutide initiators and SGLT2i initiators, respectively (hazard ratio [HR], 0.99; 95% CI, 0.93-1.06; P = 0.86). For suicide attempts or deaths, the incidence rates were 4.30 and 2.64 per 1000 person-years, respectively (HR, 1.05; 95% CI, 0.84-1.31; P = .86). In adherence-adjusted analyses, sustained semaglutide treatment for more than 12 months, compared with 6 or fewer months, was associated with a 74% lower risk of suicide attempts or deaths (HR, 0.27; 95% CI, 0.14-0.54; P<.001). Conclusion: Among U.S. Veterans with type 2 diabetes, initiators of semaglutide were not observed to have an increased risk of suicidality compared with initiators of SGLT2i. Those with longer semaglutide treatment (beyond 12 months) had decreased risk of suicide attempt or death, suggesting longer term treatment is safe and may protect against for those outcomes.

  • Open Access

    Increased Risk of New Onset NAION for Initiators of Semaglutide with Type 2 Diabetes in the U.S. Veterans Health Administration

    by Kent Heberer, Adam Bress, Steven Cogill, Ana I. Maldonado, Sun H. Kim, Shriram Nallamshetty, Ying Q. Chen, Mei-Chung Shih, Julie A. Lynch, Jennifer S. Lee

    Importance: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are among the safest and most effective medications for diabetes and weight loss and are currently used by millions of individuals worldwide. While their cardiometabolic benefits are well established, emerging observational reports have raised concerns about a potential association between GLP-1 RA use and new-onset non-arteritic anterior ischemic optic neuropathy (NAION). Objective: To emulate a target trial evaluating the risk of NAION associated with initiation of semaglutide, a GLP-1RA, compared with a sodium-glucose cotransporter-2 inhibitor (SGLT2i) as second-line therapy for type 2 diabetes in a nationwide cohort of U.S. Veterans. Design: Active-comparator, new-user, target trial emulation. Marginal cause-specific hazard ratios (HRs) were estimated using overlap weighting to account for confounding. Data analysis was conducted from July 2025 to September 2025. Setting: The Veterans Health Administration (VHA) nationwide health care system between March 1, 2018 and March 1, 2025. Participants: U.S. Veterans with a diagnosis of type 2 diabetes who were current metformin users and had no prior exposure to GLP-1RAs or SGLT2is. Exposure: Initiation of semaglutide or any SGLT2i. Main Outcome and Measure: Incident NAION, identified using ICD-10 and SNOMED diagnosis codes. Results: A total of 102,361 Veterans met inclusion criteria, including 11,478 new initiators of semaglutide and 90,883 new initiators of an SGLT2i. Baseline characteristics were well balanced between treatment groups after overlap weighting (mean [SD] age, 60.1 [11.7] years; BMI, 37.8 [6.7] kg/m 2 ; hemoglobin A1c, 7.0% [1.4]; 85.5% male; 61.9% non-Hispanic White; 20.7% Black; 8.1% Hispanic). Over a median follow-up of 2.1 years, 153 total incident NAION events occurred. The incidence rate of NAION was 123 per 100,000 person-years among semaglutide initiators and 67 per 100,000 person-years among SGLT2i initiators. Patients who initiated semaglutide had a 2.33-fold higher risk than patients who initiated SGLT2i (HR, 2.33; 95% CI, 1.54–3.54; P<.001). Conclusions and Relevance: In this nationwide cohort of U.S. Veterans with type 2 diabetes, patients who initiated semaglutide had over a 2-fold increased risk of NAION compared to patients who initiated SGLT2i.

  • Open Access

    Genomics-Informed Drug Repurposing Strategy Identifies Novel Therapeutic Targets for Metabolic Dysfunction-Associated Steatotic Liver Disease

    by Hannah M. Seagle, Alexis T. Akerele, Joseph A. DeCorte, Jacklyn N. Hellwege, Joseph H. Breeyear, Jeewoo Kim, Michael Levin, Samuel Khodurksy, Adam Bress, Kyung Lee, et al.

    Summary: Identification of drug-repurposing targets with genetic and biological support is an economically and temporally efficient strategy for improving treatment of diseases. We employed a cross-disciplinary approach to identify potential treatments for metabolic dysfunction associated steatotic liver disease (MASLD) using humans as a model organism. We identified 212 putative causal genes associated with MASLD using data from a large multi-ancestry genetic association study, of which 158 (74.5%) are novel. From this set we identified 57 genes that encode for druggable protein targets, and where the effects of increasing genetically predicted gene expression on MASLD risk align with the function of that drug on the protein target. These potential targets were then evaluated for evidence of efficacy using Mendelian randomization, pathway analysis, and protein structural modeling. Using these approaches, we present compelling evidence to suggest activation of FADS1 by icosopent ethyl as well as S1PR2 by fingolimod could be promising therapeutic strategies for MASLD.


  • Open Access

    Predicting clinical outcomes of SARS-CoV-2 infection during the Omicron wave using machine learning

    by Steven Cogill, Shriram Nallamshetty, Natalie Fullenkamp, Kent Heberer, Julie Lynch, Kyung Min Lee, Mihaela Aslan, Mei-Chiung Shih, Jennifer S. Lee

    The Omicron SARS-CoV-2 variant continues to strain healthcare systems. Developing tools that facilitate the identification of patients at highest risk of adverse outcomes is a priority. The study objectives are to develop population-scale predictive models that: 1) identify predictors of adverse outcomes with Omicron surge SARS-CoV-2 infections, and 2) predict the impact of prioritized vaccination of high-risk groups for said outcome. We prepared a retrospective longitudinal observational study of a national cohort of 172,814 patients in the U.S. Veteran Health Administration who tested positive for SARS-CoV-2 from January 15 to August 15, 2022. We utilized sociodemographic characteristics, comorbidities, and vaccination status, at time of testing positive for SARS-CoV-2 to predict hospitalization, escalation of care (high-flow oxygen, mechanical ventilation, vasopressor use, dialysis, or extracorporeal membrane oxygenation), and death within 30 days. Machine learning models demonstrated that advanced age, high comorbidity burden, lower body mass index, unvaccinated status, and oral anticoagulant use were the important predictors of hospitalization and escalation of care. Similar factors predicted death. However, anticoagulant use did not predict mortality risk. The all-cause death model showed the highest discrimination (Area Under the Curve (AUC) = 0.903, 95% Confidence Interval (CI): 0.895, 0.911) followed by hospitalization (AUC = 0.822, CI: 0.818, 0.826), then escalation of care (AUC = 0.793, CI: 0.784, 0.805). Assuming a vaccine efficacy range of 70.8 to 78.7%, our simulations projected that targeted prevention in the highest risk group may have reduced 30-day hospitalization and death in more than 2 of 5 unvaccinated patients.


  • Open Access

    Predicting Clinical Outcomes of SARS-CoV-2 Infection During the Omicron Wave Using Machine Learning

    by Steven Cogill, Shriram Nallamshetty, Natalie Fullenkamp, Kent Heberer, Julie Lynch, Kyung Min Lee, Mihaela Aslan, Mei-Chiung Shih, Jennifer S Lee

    The Omicron SARS-CoV-2 variant continues to strain healthcare systems. Developing tools that facilitate the identification of patients at highest risk of adverse outcomes is a priority. The study objectives are to develop population-scale predictive models that: 1) identify predictors of adverse outcomes with Omicron surge SARS-CoV-2 infections, and 2) predict the impact of prioritized vaccination of high-risk groups for said outcome. We prepared a retrospective longitudinal observational study of a national cohort of 192,984 patients in the U.S. Veteran Health Administration who tested positive for SARS-CoV-2 from January 15 to August 15, 2022. We utilized sociodemographic characteristics, comorbidities, vaccination status, and prior COVID-19 infections, at time of testing positive for SARS-CoV-2 to predict hospitalization, escalation of care (high-flow oxygen, mechanical ventilation, vasopressor use, dialysis, or extracorporeal membrane oxygenation), and death within 30 days. Machine learning models demonstrated that advanced age, high comorbidity burden, lower body mass index, unvaccinated status, prior SARS-CoV-2 infection, and oral anticoagulant use were the important predictors of hospitalization and escalation of care. Similar factors predicted death. However, prior SARS-CoV-2 infection was associated with lower 30-day mortality, and anticoagulant use did not predict mortality risk. The all-cause death model showed the highest discrimination (Area Under the Curve (AUC) = 0.895, 95% Confidence Interval (CI): 0.885, 0.906) followed by hospitalization (AUC = 0.829, CI: 0.825, 0.834), then escalation of care (AUC=0.805, CI: 0.795, 0.814). Assuming a vaccine efficacy range of 70.8 to 78.7%, our simulations projected that targeted prevention in the highest risk group may have reduced 30-day hospitalization, care escalation, and death in more than 2 of 5 unvaccinated patients.

  • Kinematic changes in gait in boys with Duchenne Muscular Dystrophy: Utility of the Gait Deviation Index, the Gait Profile Score and the Gait Variable Scores

    by Susan Sienko, Cathleen Buckon, Anita Bagley, Eileen Fowler, Kent Heberer, Loretta Staudt, Mitell Sison-Williamson, Craig McDonald, Michael Sussman


  • Hip kinetics during gait are clinically meaningful outcomes in young boys with Duchenne muscular dystrophy

    by Kent Heberer, Eileen Fowler, Loretta Staudt, Susan Sienko, Cathleen E. Buckon, Anita Bagley, Mitell Sison-Williamson, Craig M. McDonald, Michael D. Sussman